These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34497008)

  • 21. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial.
    Lee MMY; Kristensen SL; Gerstein HC; McMurray JJV; Sattar N
    Diabetes Metab Syndr; 2022 Jan; 16(1):102382. PubMed ID: 35030451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease.
    Smilowitz NR; Donnino R; Schwartzbard A
    Circulation; 2014 Jun; 129(22):2305-12. PubMed ID: 24891623
    [No Abstract]   [Full Text] [Related]  

  • 24. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.
    Bellastella G; Maiorino MI; Longo M; Scappaticcio L; Chiodini P; Esposito K; Giugliano D
    Stroke; 2020 Feb; 51(2):666-669. PubMed ID: 31813360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
    Varin EM; McLean BA; Lovshin JA
    Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The early use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk].
    Nardi F; Di Fusco SA; Spinelli A; Aquilani S; Riccio C; Caldarola P; De Luca L; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Apr; 24(4):285-292. PubMed ID: 36971172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 29. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Mar; 161():108087. PubMed ID: 32084455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time.
    Caruso I; Cignarelli A; Laviola L; Giorgino F
    Diabetes Care; 2022 Feb; 45(2):e30-e31. PubMed ID: 35020816
    [No Abstract]   [Full Text] [Related]  

  • 32. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
    Lingvay I; Leiter LA
    Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
    [No Abstract]   [Full Text] [Related]  

  • 34. Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic.
    Patoulias D; Boulmpou A; Imprialos K; Stavropoulos K; Papadopoulos C; Doumas M
    Rev Clin Esp (Barc); 2022 Apr; 222(4):229-232. PubMed ID: 34167924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.
    Vaduganathan M; Patel RB; Singh A; McCarthy CP; Qamar A; Januzzi JL; Scirica BM; Butler J; Cannon CP; Bhatt DL
    J Am Coll Cardiol; 2019 Apr; 73(12):1596-1598. PubMed ID: 30922481
    [No Abstract]   [Full Text] [Related]  

  • 37. Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?
    Monnier L; Colette C; Bonnet F; Owens D
    Diabetes Metab; 2020 Sep; 46(4):261-264. PubMed ID: 32035226
    [No Abstract]   [Full Text] [Related]  

  • 38. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.
    Bajaj HS; Al-Jabri B; Verma S
    Curr Opin Cardiol; 2018 Nov; 33(6):665-675. PubMed ID: 30142096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.
    Song R; Qian H; Wang Y; Li Q; Li D; Chen J; Yang J; Zhong J; Yang H; Min X; Xu H; Yang Y; Chen J
    J Diabetes Res; 2022; 2022():4554996. PubMed ID: 35434139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.